Wilmington, DE – According to filings with the U.S. Securities and Exchange Commission, Ufovax is raising $20,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ji Li played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ufovax

Founded in early 2018, Ufovax, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

To learn more about Ufovax, visit http://www.ufovax.com/

Contact:
Ji Li, President and Chief Executive Officer
302-364-0363
https://www.linkedin.com/in/ji-li-aba15b3a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved